in-cumbria.com9h
End of an era for pharmaceutical giant GSK
A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...
Hosted on MSN15h
GSK stays optimistic on vaccines amidst US and China woes
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
GSK Shares Jump After Drugmaker Boosts Outlook, Positive Quarterly Results
American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...
GSK lifts long-term sales targets on new drug pipeline
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It ...
European markets open mixed ahead of more earnings reports; GSK up 6%
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
The Independent on MSN10d
Cancer vaccine being created by UK scientists could stop disease up to 20 years early
A new partnership between the University of Oxford and GSK aims to develop vaccines against cancer before develop ...
FierceBiotech24d
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...